Deutetrabenazine Oral Capsule
Approved
Deutetrabenazine Oral Capsule is one of 18 therapeutic programs targeting Tardive Dyskinesia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
25 competitors in Tardive Dyskinesia
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Zyprexa
MMODAG GmbH
Approved
Austedo
TevaApproved
Risperdal
WWim Janssens
Approved
Barhemsys
AAcacia Pharma Ltd
Approved
Abilify
OtsukaApproved
Reminyl
WWim Janssens
Approved
Eicosapentaenoic Acid
SS.L.A. Pharma AG
Approved
Inderal
Mylan Pharmaceuticals IncPhase 3
Piracetam
UCBPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tardive Dyskinesia1 trial
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]